A hypoglycemic and hypolipidemic composition from the leaves of embelia laeta and its preparation and use

Abstract

The application discloses a hypoglycemic and hypolipidemic composition from the leaves of pandamus, a preparation method and application thereof. The composition contains p-coumaric acid, rutin, kaempferol-3-O-rutinoside, pandamarilactonine-A, pandamarilactone-1 and pandamarilactone-2. The composition with a preferred mass ratio has a certain synergistic effect. Under the premise of a consistent total dose, the composition is superior to p-coumaric acid, rutin and kaempferol-3-O-rutinoside in improving insulin resistance and reducing fat deposition, and is also superior to a pandamus alkaloid composition composed of pandamarilactonine-A, pandamarilactone-1 and pandamarilactone-2, which indicates that there is a synergistic effect among the components of the composition.

Description

TECHNICAL FIELD

[0001] The present application belongs to the field of medicine, and particularly relates to a blood glucose and blood lipid reducing composition from Pandanus amaryllifolius Roxb. and a preparation method and use thereof. BACKGROUND

[0002] In recent years, diabetes and dyslipidemia have become serious metabolic diseases worldwide. Diabetes is a chronic metabolic disease caused by insufficient or dysfunctional insulin secretion. Dyslipidemia is an important risk factor for cardiovascular disease and is closely related to atherosclerosis, coronary heart disease and stroke. Diabetes and dyslipidemia often occur together and influence each other, exacerbating insulin resistance and increasing the risk of cardiovascular disease. With changes in lifestyle and the aging of the population, the incidence of diabetes and hyperlipidemia continues to rise, showing a trend of younger onset.

[0003] Pandanus amaryllifolius Roxb., also known as Pandanus amaryllifolius, is the only plant in the Pandanaceae family with a fragrant odor. It is widely used in food processing due to its unique "rice dumpling fragrance" flavor. In the 1950s, Pandanus amaryllifolius Roxb. was introduced to China and successfully cultivated in Hainan, Taiwan, Yunnan, Guangdong and other places. As a typical tropical economic crop, Pandanus amaryllifolius Roxb. not only has high economic value, but also has broad development prospects. Traditional medicine believes that it can be used to treat hyperglycemia, hypertension, gout and rheumatism.

[0004] Current research on the blood glucose and blood lipid reducing effect of Pandanus amaryllifolius Roxb. is limited to preliminary efficacy verification of whole crude extract, and lacks systematic active site screening research. Based on the screening of active sites in Pandanus amaryllifolius Roxb., the present application provides an effective blood glucose and blood lipid reducing composition. SUMMARY

[0005] The purpose of the present application is to provide a blood glucose and blood lipid reducing composition from Pandanus amaryllifolius Roxb. and a preparation method and use thereof.

[0006] The blood glucose and blood lipid reducing composition of the present application contains p-coumaric acid, rutin, kaempferol-3-O-rutinoside, pandamarilactonine-A, pandamarilactone-1 and pandamarilactone-2.

[0007] Preferably, it contains p-coumaric acid 15-35%, rutin 5-20%, kaempferol-3-O-rutinoside 5-20%, pandamarilactonine-A 15-20%, pandamarilactone-1 15-20% and pandamarilactone-2 15-20% by mass fraction.

[0008] Preferably, the mass ratio of p-coumaric acid, rutin, kaempferol-3-O-rutinoside, pandamarilactonine-A, pandamarilactone-1, and pandamarilactone-2 is 33:5:8:19:16:19.

[0009] Preferably, the medicine prepared from the above-mentioned hypoglycemic and hypolipidemic composition comprises a pharmaceutically acceptable carrier, solvent, diluent, excipient or other medium, and can be prepared into a corresponding powder, granule, capsule, injection, oral liquid or tablet as required.

[0010] The present application also provides a preparation method of the above-mentioned hypoglycemic and hypolipidemic composition, which comprises uniformly mixing the components.

[0011] The present application also provides an application of the above-mentioned hypoglycemic and hypolipidemic composition in preparing a medicine with hypoglycemic and hypolipidemic effects.

[0012] The above-mentioned composition has the effects of relieving insulin resistance and fat deposition, and thus has application values in hypoglycemic and hypolipidemic aspects, and the applications thereof include but are not limited to preparing the composition into a medicine with hypoglycemic and hypolipidemic effects.

[0013] The present application has the following advantages:

[0014] (1) The present application systematically screens the active part of Piper methysticum based on the commonly used insulin resistance and fat deposition cell model, and first determines the hypoglycemic and hypolipidemic active part of Piper methysticum.

[0015] (2) The composition is formed by constructing the composition with the main compounds in the active part of Piper methysticum through the component analysis of the hypoglycemic and hypolipidemic active part of Piper methysticum, and the activity of the formed composition is better than that of the active part of Piper methysticum.

[0016] (3) The composition with the preferred mass ratio has a certain synergistic effect, and the effect of improving insulin resistance and reducing fat deposition is better than that of p-coumaric acid, rutin and kaempferol-3-O-rutinoside, and also better than that of the Piper methysticum alkaloid composition composed of pandamarilactonine-A, pandamarilactone-1 and pandamarilactone-2, which indicates that there is a synergistic effect between the components of the composition. BRIEF DESCRIPTION OF DRAWINGS

[0017] Figure 1 A graph of the effect of each extract part of Piper methysticum on the triglyceride deposition amount in HePG2 cells;

[0018] Figure 2Figure for the effect of each extract of Pandanus amaryllifolius on glucose consumption of HePG2 cells;

[0019] Figure 3 Figure for the liquid chromatogram of the active fraction of Pandanus amaryllifolius in Comparative Example 1, wherein 1: pandamarilactonine-A, 2: pandamarilactone-1, 3: pandamarilactone-2, 4: p-coumaric acid, 5: rutin, 6: kaempferol-3-O-rutinoside;

[0020] Figure 4 Figure for the liquid chromatogram of the alkaloid composition of Pandanus amaryllifolius in Comparative Example 2, wherein 1: pandamarilactonine-A, 2: pandamarilactone-1, 3: pandamarilactone-2;

[0021] Figure 5 Figure for the liquid chromatogram of the composition constructed in Example 1, wherein 1: pandamarilactonine-A, 2: pandamarilactone-1, 3: pandamarilactone-2, 4: p-coumaric acid, 5: rutin, 6: kaempferol-3-O-rutinoside;

[0022] Figure 6 Figure for the liquid chromatogram of the composition constructed in Example 2, wherein 1: pandamarilactonine-A, 2: pandamarilactone-1, 3: pandamarilactone-2, 4: p-coumaric acid, 5: rutin, 6: kaempferol-3-O-rutinoside;

[0023] Figure 7 Figure for the effect of each of the comparative examples, examples, and p-coumaric acid, rutin, and kaempferol-3-O-rutinoside monomers on triglyceride accumulation in HePG2 cells;

[0024] Figure 8 Figure for the effect of each of the comparative examples, examples, and p-coumaric acid, rutin, and kaempferol-3-O-rutinoside monomers on glucose consumption of HePG2 cells; DETAILED DESCRIPTION

[0025] The terms used in the present application have the meanings generally understood by those of ordinary skill in the art, unless otherwise defined

[0026] P-coumaric acid (4-Hydroxycinnamic acid) has a molecular formula of C9H8O3, a CAS number of 501-98-4, and a structural formula of:

[0027]

[0028] Rutin, molecular formula is C 27 H 30 O 16 , CAS number: 153-18-4, structural formula is:

[0029]

[0030] Kaempferol 3-rutinoside, molecular formula is C 27 H 30 O 15 , CAS number: 17650-84-9, structural formula is:

[0031]

[0032] pandamarilactonine-A, molecular formula is: C 18 H 23 NO4, CAS number: 303008-80-2, structural formula is:

[0033]

[0034] pandamarilactone-1, molecular formula is: C 18 H 23 NO4, CAS number: 152606-63-8, structural formula is:

[0035]

[0036] pandamarilactone-2, molecular formula is: C 18 H 23 NO4, CAS number: 1814904-51-2, structural formula is:

[0037]

[0038] The essential content of the present application will be specifically described below in combination with the drawings and examples, but the protection scope of the present application is not limited by this.

[0039] Comparative Example 1

[0040] In order to clarify the active part and components of the blood glucose and blood lipid lowering activity of the leaves of pandanus utilis, the effects of different extraction parts of the leaves of pandanus utilis on glucose uptake, lipid accumulation, insulin sensitivity and other indicators were evaluated by cell experiment system, the active part with clear effect was screened out, and the components of the active part were studied.

[0041] 1. Different extraction fractions of Spigelia anthemia leaves

[0042] Take about 50 g of dried Spigelia anthemia leaf sample (cut into small pieces) and place it in a round-bottom flask. Add 1000 mL and 800 mL of water respectively and heat to a slight boil for two extractions, each for 1 hour. Filter and combine the two extraction solutions. Evaporate to dryness to obtain the water extract of Spigelia anthemia leaves (Fr1, 50 g → 9.69 g).

[0043] Take about 250 g of dried Spigelia anthemia leaf sample (cut into small pieces) and place it in a round-bottom flask. Add 5 L and 4 L of water respectively and heat to a slight boil for two extractions, each for 1 hour. Filter and combine the two extraction solutions. Concentrate and then use macroporous resin separation. Elute with water, 20% ethanol, 40% ethanol, and 60% ethanol in sequence, 6 column volumes for each solvent. Evaporate each eluate to dryness to obtain Fr2-Fr5 (250 g → 40.68 g, 3.94 g, 2.92 g, 0.60 g).

[0044] Take about 50 g of dried Spigelia anthemia leaf powder and place it in a round-bottom flask. Add 500 mL of 95% ethanol solution for each extraction, heat to a slight boil in a water bath for two extractions, each for 1 hour. Filter and combine the two extraction solutions. Evaporate to dryness to obtain the 95% ethanol extract of Spigelia anthemia leaves (Fr6, 50 g → 7.92 g).

[0045] Take about 100 g of dried Spigelia anthemia leaf powder and place it in a round-bottom flask. Add 1000 mL of 95% ethanol solution for each extraction, heat to a slight boil in a water bath for two extractions, each for 1 hour. Filter and combine the two extraction solutions. Concentrate to remove the alcohol taste and transfer to a separatory funnel. Extract with petroleum ether, ethyl acetate, and n-butanol in sequence, 3 times for each solvent. The remaining liquid is the water fraction. Evaporate each fraction to dryness to obtain Fr7-Fr10 (100 g → 4.35 g, 1.84 g, 2.05 g, 3.67 g).

[0046] Take about 50 g of dried Spigelia anthemia leaf powder and place it in a round-bottom flask. Add 500 mL of ethyl acetate for each extraction, heat to a slight boil in a water bath for two extractions, each for 1 hour. Filter and combine the two extraction solutions. Evaporate to dryness to obtain the ethyl acetate extract of Spigelia anthemia leaves (Fr11, 50 g → 1.08 g).

[0047] 2. Effect of each fraction extract of Spigelia anthemia leaves on HepG2 cell fat deposition

[0048] Each extract was tested on a HepG2 cell fat deposition model induced by free fatty acids.

[0049] Preparation of free fatty acids: 1 g and 2 g of fatty acid-free bovine serum albumin (BSA) were weighed and added to 5 ml of deionized water, respectively, to obtain 20% and 40% BSA solutions, respectively. 0.06 g of sodium hydroxide (NaOH) was weighed and added to 10 ml of deionized water to obtain a 0.15 mM NaOH solution, which was divided into two parts. One part was added with 63.47 μl of oleic acid, and the other part was added with 0.025624 g of palmitic acid. Both were placed in a 75 °C water bath for saponification for 30 min to obtain 40 mM oleic acid and 20 mM palmitic acid solutions. Immediately, the 40% and 20% BSA solutions were mixed with the 40 mM oleic acid and 20 mM palmitic acid solutions, respectively, to obtain 20 mM oleic acid and 10 mM palmitic acid solutions. The pH value was adjusted to be similar to that of the culture medium using hydrochloric acid. After sterilization by filtration, the solutions were stored at 4 °C for later use. Before use, the oleic acid and palmitic acid solutions were mixed, and the culture medium was used to dilute them to the desired concentration. 1.5 g of BSA was weighed and added to 10 mL of deionized water to obtain a 15% BSA solution as a control solvent. After sterilization by filtration, the solution was stored at 4 °C for later use.

[0050] Based on the experimental requirements, a free fatty acid concentration (0.6 mM, oleic acid:palmitic acid = 2:1) that had little effect on cell activity was selected to induce the formation of a cell lipid deposition model. HepG2 cells in the logarithmic growth phase were inoculated in a 24-well cell culture plate at an appropriate density and incubated overnight at 37 °C in a 5% CO2 cell incubator. After the cells adhered, they were treated according to the following groups:

[0051] (1) Solvent control group: DMEM complete medium containing 0.6% BSA and 0.1% DMSO was added;

[0052] (2) Model group: complete medium containing 0.4 mM and 0.2 mM oleic acid and palmitic acid, respectively, and 0.6% BSA and 0.1% DMSO was added;

[0053] (3) Positive drug group: complete medium containing 0.4 mM and 0.2 mM oleic acid and palmitic acid, respectively, 50 μM lovastatin, and 0.6% BSA and 0.1% DMSO was added;

[0054] (4) Banlan leaf extract low, medium, and high dose groups: complete medium containing 0.4 mM and 0.2 mM oleic acid and palmitic acid, respectively, and an appropriate concentration of Banlan leaf extract, and 0.6% BSA and 0.1% DMSO was added;

[0055] Each group was treated for 24 hours. The triglyceride content in the HepG2 cells was detected using a triglyceride detection kit, and the total protein content was normalized. The results are shown in FIG. 1. Figure 1

[0056] ​The results showed that Fr8, the ethyl acetate extract of the 95% ethanol extract of the leaves of P. insularis, had the most significant effect on reducing fat deposition.

[0057] 3. Effects of extracts from different parts of P. insularis on insulin resistance in HepG2 cells

[0058] The insulin resistance model of HepG2 cells was induced by high glucose and palmitic acid, and each extract was tested. Insulin-resistant cells have decreased glucose uptake and utilization, and abnormal glucose metabolism. Therefore, the glucose consumption of HepG2 cells was used as an indicator in this experiment.

[0059] The preparation method of the palmitic acid mother liquor was the same as above.

[0060] HepG2 cells in the logarithmic growth phase were inoculated in 24-well cell culture plates at an appropriate density, and incubated overnight at 37°C in a 5% CO2 cell incubator. After the cells adhered, they were treated according to the following groups:

[0061] Solvent control group: add DMEM low glucose basic medium containing 0.1% BSA and 0.1% DMSO (glucose concentration 5 mM);

[0062] Model group: add high glucose basic medium containing 0.1 mM palmitic acid (glucose concentration 25 mM, containing 0.1% BSA and 0.1% DMSO);

[0063] Positive drug group: add high glucose basic medium containing 0.1 mM palmitic acid and 1 mM metformin (glucose concentration 25 mM, containing 0.1% BSA and 0.1% DMSO);

[0064] P. insularis extract low, medium, and high dose groups: add high glucose basic medium containing 0.1 mM palmitic acid and appropriate concentrations of P. insularis extract (glucose concentration 25 mM, containing 0.1% BSA and 0.1% DMSO);

[0065] After treating the cells in each group for 24 hours, the cell supernatant was replaced with 10 mM glucose basic medium, and incubated for 12 hours. The glucose consumption was measured and normalized with the cell viability detection results, and the results are shown in FIG. Figure 2

[0066] ​Fr4 (macaranga tanarius leaf water extract macroporous resin 40% ethanol elution fraction), Fr8 (macaranga tanarius leaf 95% ethanol extract ethyl acetate extraction fraction), Fr9 (macaranga tanarius leaf 95% ethanol extract n-butanol extraction fraction) and positive control metformin group can increase the glucose consumption of HepG2 cells compared with the model group. Among them, Fr8 and Fr9 have equivalent effects on increasing glucose consumption. Combined with the results of the lipid-lowering experiment, Fr8, i.e., the macaranga tanarius leaf 95% ethanol extract ethyl acetate extraction fraction, is selected as the active site for reducing fat deposition and relieving insulin resistance.

[0067] 4. Active site component analysis of macaranga tanarius leaf

[0068] The macaranga tanarius leaf 95% ethanol extract ethyl acetate extraction fraction was qualitatively analyzed by UFLC-Triple TOF-MS / MS technology, and six main compounds were quantitatively detected. The liquid chromatography conditions were as follows: a C18 chromatographic column (Accucore C18 150×2.1 mm, 2.5 μm, SN: A266008, ACE, UK) was used, the column temperature was 40 ℃, 0.1% formic acid solution was used as mobile phase A, and methanol was used as mobile phase B, gradient elution: 0→30 min, A: 10%→70%; 30→35 min, A: 70%→100%; 35→45 min, A: 100%, the flow rate was 0.3 mL / min. The mass spectrometry conditions were as follows: an electrospray ion source (ESI) was used, information-dependent acquisition (IDA) was used, dynamic background subtraction (DBS) was turned on, and detection was performed in positive and negative ion modes. The ESI ion source parameters were as follows: GS1 55 psi, GS2 55 psi, CUR 35 psi, TEM 550 ℃, positive mode ISVF 5500 V, negative mode ISVF -4500 V. The compound-related parameters were as follows: DP 80 V, CE 35 eV, CES 15 eV. The atomization gas and auxiliary gas were both nitrogen, the mass to charge (m / z) range was 50~1500 Da, and the data were collected using Analyst®1.2 software.

[0069] In the active site of macaranga tanarius leaf, i.e., the macaranga tanarius leaf 95% ethanol extract ethyl acetate extraction fraction, a total of 27 compounds were detected, mainly alkaloids, flavonoids, and organic acids, as shown in Table 1.

[0070] Table 1

[0071] No. Compound Name Molecular Formula CAS No. Classification 1 Pandamarilactonine-A C 18 H 23 NO4]]> 303008-80-2 Alkaloid 2 Pandamarilactone-1 C 18 H 23 NO4]]> 152606-63-8 Alkaloid 3 Pandamarilactone-2 [C 18 H 23 NO4]]> 1814904-51-2 Alkaloid 4 Pandamarilactone-32 C 18 H 21 NO3]]> 152606-65-0 Alkaloid 5 5(E)-Pandamarilactonine 32 C 18 H 21 NO3]]> 1814904-58-9 Alkaloid 6 Pandamarilactam-3x(2-Pyrrolidinone) C 13 H 17 NO3]]> 189179-33-7 Alkaloid 7 Pandamarilactam-3y(2-Pyrrolidinone) C 13 H 17 NO3]]> 189179-35-9 Alkaloid 8 Kaempferol-3-O-rutinoside C 27 H 30 O 15 ]]> 17650-84-9 Flavonoid 9 Rutin C 27 H 30 O 16 ]]> 153-18-4 Flavonoid 10 p-Coumaric Acid [C9H8O3] 501-98-4 Organic Acid 11 Zephyranthine C 28 H 32 O 16 ]]> 604-80-8 Flavonoid 12 Astrin C 21 H 20 O 11 ]]> 480-10-4 Flavonoid 13 Linoleic Acid C 18 H 32 O2]]> 60-33-3 Organic Acid 14 Chlorogenic Acid C 16 H 18 O9]]> 327-97-9 Organic Acid 15 L-Malic Acid [C4H6O5] 97-67-6 Organic Acid 16 Isochlorogenic Acid B C 25 H 24 O 12 ]]> 2450-53-5 Organic Acid 17 Isochlorogenic Acid C C 25 H 24 O 12 ]]> 57378-72-0 Organic Acid 18 Quinic Acid [C7H 12 O6]]> 77-95-2 Organic Acid 19 Adenosine C 10 H 13 N5O4]]> 58-61-7 Nucleoside 20 Vitexin C 21 H 20 O 10 ]]> 3681-93-4 Flavonoid 21 Isovitexin C 21 H 20 O 10 ]]> 29702-25-8 Flavonoid 22 Shikimic Acid [C7H 10 O5]]> 138-59-0 Organic Acid 23 Isoambroxide C 26 H 28 O 14 ]]> 52012-29-0 Flavonoid 24 Ambroxide C 26 H 28 O 14 ]]> 51938-32-0 Flavonoid 25 Protocatechuic Acid [C7H6O4] 99-50-3 Organic Acid 26 Cinnamic Acid [C9H8O2] 621-82-9 Organic Acid 27 Naringin C 27 H 32 O 14 ]]> 10236-47-2 Flavonoid

[0072] The main compounds with high content in the active site of macaranga tanarius leaf, i.e., the macaranga tanarius leaf 95% ethanol extract ethyl acetate extraction fraction, are six kinds, and the HPLC chromatogram is shown in the following figure:Figure 3 The six compounds were quantitatively detected by liquid chromatography-mass spectrometry, and the results were as follows: p-coumaric acid 7.82%, rutin 1.33%, kaempferol-3-O-rutinoside 1.96%, pandamarilactonine-A 4.50%, pandamarilactone-1 3.86%, and pandamarilactone-2 4.55%. The mass ratio of each compound was about 33:5:8:19:16:19, and the composition was subsequently constructed in the ratio.

[0073] Comparative Example 2

[0074] A pandamarilactone composition was constructed in the mass ratio of pandamarilactonine-A, pandamarilactone-1, and pandamarilactone-2 19:16:19. The difference between the composition of this comparative example and the preferred ratio composition was that only alkaloids were contained, and the HPLC chromatogram is shown in FIG. 2. Figure 4 .

[0075] Example 1

[0076] A composition was constructed by mixing p-coumaric acid, rutin, kaempferol-3-O-rutinoside, pandamarilactonine-A, pandamarilactone-1, and pandamarilactone-2 in the mass ratio of 33:5:8:19:16:19, and the HPLC chromatogram is shown in FIG. 3. Figure 5 .

[0077] Example 2

[0078] A composition was constructed by mixing p-coumaric acid, rutin, kaempferol-3-O-rutinoside, pandamarilactonine-A, pandamarilactone-1, and pandamarilactone-2 in the mass ratio of 1:1:1:1:1:1, and the HPLC chromatogram is shown in FIG. 4. Figure 6 .

[0079] The 95% ethanol extract of Pandanus utilis leaves in Comparative Example 1, the ethyl acetate extract part Fr8, Comparative Example 2, Example 1, Example 2, and p-coumaric acid, rutin, and kaempferol-3-O-rutinoside were evaluated for reducing fat deposition and relieving insulin resistance activity in the above-mentioned free fatty acid-induced HePG2 cell fat deposition model and high glucose+palmitic acid-induced HePG2 cell insulin resistance model, respectively. The triglyceride detection results in the cells are shown in FIG. 5, and the glucose consumption capacity of the cells is shown in FIG. 6. Figure 7 Figure 8 ​The experimental results show that the active part of the leaves of P. odoratum in Comparative Example 1, Comparative Example 2, Example 1, Example 2, and p-coumaric acid, rutin, and kaempferol-3-O-rutinoside can effectively reduce fat deposition in HePG2 cells and relieve insulin resistance.

[0080] The inhibition rate of each composition or monomer on fat deposition in HePG2 cells and the promotion rate of each composition or monomer on glucose consumption in HePG2 cells at a concentration of 100 μg / ml are shown in Table 2.

[0081] Table 2

[0082] Serial No. Test Sample Fat Deposition Inhibition Rate Glucose Consumption Promotion Rate 1 Active Fraction of P. paniculata Leaf in Comparative Example 1 13.73±2.41% 13.06±2.77% 2 Comparative Example 2 19.75±3.70% 24.60±3.93% 3 Example 1 38.52±4.93% 55.41±5.75% 4 Example 2 30.86±3.11% 45.63±6.96% 5 p-Coumaric Acid 25.12±3.97% 27.29±4.33% 6 Rutin 31.18±3.53% 51.29±5.84% 7 Kaempferol-3-O-rutinoside 27.69±5.49% 39.39±5.06%

[0083] In summary, the active part of the leaves of P. odoratum is screened based on the free fatty acid-induced fat deposition model of HePG2 cells and the high glucose + palmitic acid-induced insulin resistance model of HePG2 cells in the art, and the composition constructed from the main components of the active part of the leaves of P. odoratum, i.e., p-coumaric acid, rutin, kaempferol-3-O-rutinoside, pandamarilactonine-A, pandamarilactone-1, and pandamarilactone-2, can effectively reduce fat deposition and improve insulin resistance. The fat deposition inhibition rate and the promotion rate of glucose consumption of the composition with a mass ratio of 33:5:8:19:16:19 are significantly better than those of the active part of the leaves of P. odoratum, the alkaloid composition of the leaves of P. odoratum, and each monomer compound of p-coumaric acid, rutin, and kaempferol-3-O-rutinoside, indicating that there is a synergistic effect between the components of the composition.

[0084] The above examples serve to specifically introduce the essential content of the present application, but those skilled in the art should know that the protection scope of the present application should not be limited to the specific examples.

Claims

1. A blood sugar lowering and blood lipid lowering composition, characterized in that, consisting of p-coumaric acid, rutin, kaempferol-3-O-rutinoside, pandamarilactonine-A, pandamarilactone-1 and pandamarilactone-2, and the mass ratio of p-coumaric acid, rutin, kaempferol-3-O-rutinoside, pandamarilactonine-A, pandamarilactone-1 and pandamarilactone-2 is 33:5:8:19:16:

19.

2. A medicament, characterized by comprising: The medicine consists of the blood sugar and blood lipid reducing composition of claim 1 and a pharmaceutically acceptable carrier, solvent or diluent.

3. The medicament according to claim 2, characterized in that, According to different needs, the medicine is prepared into corresponding powder, granule, capsule, injection, oral liquid or tablet.

4. A process for the preparation of the hypoglycemic and hypocholesterolemic composition as claimed in claim 1, wherein, The ingredients are mixed uniformly.

5. Use of the blood sugar and blood lipid reducing composition of claim 1 in the preparation of a medicine with blood sugar and blood lipid reducing effect.

Images